Nuvectis Pharma, Inc. (NVCT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Nuvectis Pharma reported revenue of $0. Net income was -$26.4M, or -$1.32 per diluted share. Operating activities generated -$16.0M of cash. At fiscal year end, Nuvectis Pharma held $31.7M in total assets against $13.3M in total liabilities, including $31.6M of cash and equivalents.
Open the full interactive Nuvectis Pharma financials → Quarterly statements, key ratios, valuation history and price charts.
Nuvectis Pharma Key Stats
| Share Price | $18.15 |
|---|---|
| Market Cap | $426.1M |
| 52-Week Range | $5.65 – $28.53 |
| Shares Outstanding | 23.5 million (basic, 2026 Q2) |
Nuvectis Pharma Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Income | -$19.2M | -$22.9M | -$19.8M | -$27.6M |
| Pre-Tax Income | -$19.1M | -$22.3M | -$19.0M | -$26.4M |
| Net Income | -$19.1M | -$22.3M | -$19.0M | -$26.4M |
| Diluted EPS | -$1.51 | -$1.43 | -$1.11 | -$1.32 |
Nuvectis Pharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$7.5M | -$7.3M | -$6.0M | -$7.0M |
| Diluted EPS | -$0.44 | -$0.34 | -$0.26 | -$0.30 |
Nuvectis Pharma Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $20.0M | $19.1M | $18.5M | $31.6M |
| Current Assets | $20.4M | $19.2M | $18.6M | $31.7M |
| Total Assets | $20.4M | $19.2M | $18.6M | $31.7M |
| Current Liabilities | $6.2M | $7.0M | $8.9M | $13.3M |
| Total Liabilities | $6.2M | $7.0M | $8.9M | $13.3M |
| Shareholders' Equity | $14.2M | $12.2M | $9.7M | $18.4M |
Nuvectis Pharma Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$13.6M | -$16.0M | -$12.2M | -$16.0M |
| Cash From Investing | — | $0 | $0 | — |
| Cash From Financing | $27.8M | $15.1M | $11.7M | $29.1M |
Figures from Nuvectis Pharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Nuvectis Pharma financials page for every line item.
Nuvectis Pharma Company Profile
| Ticker | NVCT |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Fort Lee, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001875558 |
Frequently Asked Questions
What was Nuvectis Pharma's revenue in fiscal 2025?
Nuvectis Pharma (NVCT) reported revenue of $0 for fiscal 2025.
What is Nuvectis Pharma's annual revenue history?
Nuvectis Pharma's annual revenue by fiscal year: 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Nuvectis Pharma's net income in fiscal 2025?
Nuvectis Pharma reported net income of -$26.4M for fiscal 2025.
What was Nuvectis Pharma's earnings per share (EPS) in fiscal 2025?
Nuvectis Pharma's diluted EPS was -$1.32 for fiscal 2025 (adjusted for any later stock splits).
What was Nuvectis Pharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Nuvectis Pharma reported revenue of $0.
How many shares of Nuvectis Pharma are outstanding?
Nuvectis Pharma reported a weighted average of 23.5 million basic shares outstanding in 2026 Q2.
What is Nuvectis Pharma's market cap?
Based on its latest closing price, Nuvectis Pharma (NVCT) has a market capitalization of about $426.1M.
When does Nuvectis Pharma's fiscal year end?
Nuvectis Pharma's fiscal year end, as registered with the SEC, is December 31.
Where is Nuvectis Pharma headquartered?
Nuvectis Pharma lists its business address in Fort Lee, New Jersey in its SEC filings.